Advertisement


Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Advertisement

Advertisement




Advertisement